|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.11.25 - 02:15
|
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “Indenture”) between the Company and Odyssey Trust Company as the debenture trustee (the “Debenture Trustee”) dated May 29, 2023, governing the 12.0% convertible debentures of the Company in the aggregate principal amount of $1,454,000.00 (the "Convertible Debentures"), holders (each, a "Debentureholder") representing at least 66 2/3% of the outstanding principal of the Convertible Debentures have consented to the extension of the maturity date of the Convertible Debentures from November 29, 2025 to January 28, 2026 (the “Extension”). The Extension was approved by way of a written consent dated November 28, 20...
|
|
|
|
|
|
|
|
|
|
|
|
|
29.11.25 - 00:15
|
Cytophage Announces Closing of Non-Brokered Private Placement and Filing of Q3 Financials (The Newswire)
|
|
|
WINNIPEG, November 28, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that it has now closed the remainder of its previously announced non-brokered private placement (the “Offering”). The full details of the Offering were announced in a press release dated October 17, 2025. In connection with the closing, the Company raised an additional $198,000 of gross proceeds by issuing a total of 990,000 Units to investors, to bring the total gross proceeds to $1,200,000.
Each Unit, priced at $0.20, consists of one (1) common share of the Company (a “Share”) and one half (1/2) of a common share purchase warrant (a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one (1) additional Share ( a “Warrant Share”) at a price of C$0.40 per Warrant Share, for a period of 24 months from the date of issuance. Cytophage may accelerate the expiry of the Warrants if the volume weighted average trading pr...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
